2005
Advanced Glycosylation of LDL: Role in Oxidative Modification and Diabetic Complications
Bucala R, Makita Z, Cerami A, Vlassara H, Koschinsky T. Advanced Glycosylation of LDL: Role in Oxidative Modification and Diabetic Complications. 2005, 286-291. DOI: 10.1533/9781845698393.4.286.Peer-Reviewed Original ResearchTransition metal ionsAmine-containing phospholipidsRedox reactionsMetal ionsFree metalFacile mechanismOxidative modificationOxidationLipid oxidationApoprotein componentsMoietyGlycosylationAcid oxidationIonsAbsorbanceReactionModificationMetalsAGE moietiesFluorescencePhospholipidsPropertiesAdvanced glycosylationImmunochemical propertiesFormation
1997
Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis
Bucala R. Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis. Trends In Cardiovascular Medicine 1997, 7: 39-47. PMID: 21235862, DOI: 10.1016/s1050-1738(96)00137-5.Peer-Reviewed Original ResearchLow-density lipoproteinDiabetic patientsLDL levelsElevated LDL levelsEnzyme-linked immunosorbent assay (ELISA) techniqueRecent clinical observationsAdvanced glycosylation reactionsImmunosorbent assay (ELISA) techniqueVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallClearance mechanismsNitric oxidePatientsRadical generating systemELISA analysisAgeLipoproteinOxidative modification
1996
What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?
Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Research And Clinical Practice 1996, 30: s123-s130. PMID: 8964186, DOI: 10.1016/s0168-8227(96)80048-9.Peer-Reviewed Original ResearchConceptsDiabetic patientsLDL levelsEndothelium-derived relaxing factorsElevated LDL levelsEffects of hyperglycemiaLow-density lipoproteinRelaxing factorsVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallELISA techniqueClearance mechanismsNitric oxideClearance kineticsPatientsELISA analysisLDLAgeAminoguanidineLipoproteinSite-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis
Bucala R. Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis. Nephrology Dialysis Transplantation 1996, 11: 17-19. PMID: 9044301, DOI: 10.1093/ndt/11.supp5.17.Peer-Reviewed Original ResearchConceptsLDL receptorAGE modificationApolipoprotein BAdvanced glycosylationHuman fibroblast LDL receptorsAGE-modified formAGE-specific antibodiesRegion of apoBNon-diabetic individualsFibroblast LDL receptorLDL receptor binding siteRenal insufficiencyDiabetes mellitusDiabetic patientsElevated LDLAGE-LDLLipoprotein clearanceReceptor binding sitesHuman LDL receptorGeneral populationPlasma clearance kineticsTransgenic miceLDLAGE formationClearance kineticsThe role of advanced glycosylation end-products in the pathogenesis of atherosclerosis
Makita Z, Yanagisawa K, Kuwajima S, Bucala R, Vlassara H, Koike T. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrology Dialysis Transplantation 1996, 11: 31-33. PMID: 9044304, DOI: 10.1093/ndt/11.supp5.31.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseLow-density lipoproteinDiabetic patientsDevelopment of atherosclerosisAGE-LDLAdvanced glycosylationAGE-modified formCoronary artery diseaseSerum total cholesterolPathogenesis of atherosclerosisArtery diseaseDiabetes mellitusRenal diseaseTotal cholesterolCerebrovascular diseaseMarked elevationRapid progressionTissue injuryVascular pathologyNormal controlsPatientsAGE-modified peptidesAtherogenic formAtherosclerosisAGE modification
1995
Advanced glycosylation end products in diabetic renal and vascular disease
Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. American Journal Of Kidney Diseases 1995, 26: 875-888. PMID: 7503061, DOI: 10.1016/0272-6386(95)90051-9.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsPhase II/III clinical trialsNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesRenal functionVascular complicationsDiabetic nephropathyGlomerular sclerosisGlucose-derived Amadori productsEtiologic roleVascular diseaseClinical trialsMatrix protein synthesisTherapeutic modalitiesVascular permeabilityAdvanced glycosylationLipoprotein depositionEnd productsTissue toxicityNitric oxidePharmacologic inhibitorsToxicityProtein synthesisImmunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy
Nishino T, Horii Y, Shiiki H, Yamamoto H, Makita Z, Bucala R, Dohi K. Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Human Pathology 1995, 26: 308-313. PMID: 7890283, DOI: 10.1016/0046-8177(95)90063-2.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsGlycosylation end productsSevere diffuse lesionsAnti-AGE antibodyComplications of diabetesInner elastic layerRenal complicationsDiabetic nephropathyAGE antibodyDiffuse lesionsNondiabetic individualsVascular lesionsPathogenic roleAGE accumulationHyaline depositsImmunohistochemical stainingPositive stainingImmunohistochemical detectionAdvanced glycosylationVascular intimaNormal agingSpecific antibodiesTissue distributionEnd productsAntibodiesAdvanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts
1994
Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease
Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease. Drug Development Research 1994, 32: 77-89. DOI: 10.1002/ddr.430320204.Peer-Reviewed Original ResearchAdvanced glycosylationVascular diseasePhase II clinical trialOxidized low-density lipoproteinSpecific therapeutic modalitiesLow-density lipoproteinDirect toxic effectReversible Schiff base adductsClinical trialsAdvanced glycosylation endproductsTherapeutic modalitiesVascular permeabilityDensity lipoproteinLipoprotein depositionVascular wallELISA techniqueHeterogenous groupPathological effectsEndothelial cellsPharmacological inhibitorsPathological conditionsAgeToxic effectsLipoproteinDisease
1992
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsAdvanced glycosylationAGE-modified formAGE-specific antibodiesComplications of agingDiabetes-induced hyperglycemiaAge-related complicationsGlycosylation end productsCirculating MarkersDiabetic patientsRenal diseaseGlucose-derived Amadori productsNormal individualsComplicationsPatientsTissue modificationsTissue proteinsHemoglobinAmadori productsEnd productsPercentDiabeticsHyperglycemiaAtherosclerosisDiabetes